The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study

@article{Golouh2007ThePV,
  title={The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study},
  author={Rastko Golouh and Tanja {\vC}ufer and Aleksander Sadikov and Petra Nussdorfer and Pernille Autzen Usher and Nils Bruenner and Manfred Schmitt and Ralf Lesche and Sabine Maier and Mieke Timmermans and John A. Foekens and John W. M. Martens},
  journal={Breast Cancer Research and Treatment},
  year={2007},
  volume={110},
  pages={317-326}
}
We recently found that DNA methylation of S100A2, spleen tyrosine kinase (SYK), and Stathmin-1 (STMN1) correlates with response to tamoxifen therapy in metastatic breast cancer. In this retrospective study, we investigated immunohistochemically whether these three markers are predictors of relapse in early breast cancer (EBC) patients treated with adjuvant tamoxifen alone. Immunohistochemical staining was performed for S100A2, SYK and STMN1 on a tissue microarray containing ER-positive invasive… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 - year survival : an overview of the randomized trials

G Egger, G Liang, A Aparicio, PA Jones
Lancet • 2005

DNA methylation reliably predicts risk of recurrence in tamoxifen - treated , node - negative breast cancer patients

M Widschwendter, KD Siegmund, +5 authors PW Laird
2004

Similar Papers

Loading similar papers…